SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.500-3.1%12:19 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: galt who wrote (1191)10/17/2025 12:03:16 PM
From: jargonweary2 Recommendations

Recommended By
erippetoe
Fitzhughlaw

   of 1216
 
Absolutely agree. More tweets, more trials, greater cash needs making further dilution a possibility and the market is decidedly unimpressed. Heck, even SAVA is now outperforming IBRX. I’ll hang on a bit longer because it seems like the science behind their approved drug is real and the potential for a spike up is very possible despite the distractions of our majority owner.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News